20th World Conference on Pharmaceutical Chemistry and Drug Design

                                                                                 Neuroprotection portrays one of the most captivating therapeutic strategies for the prevention of neurodegeneration and attenuating neuronal damage. The evolution of novel neuroprotective agents has attracted stupendous drug discovery efforts, aiming towards the identification of effective neurotherapeutics for a number of central nervous system (CNS) disorders, including neurodegenerative diseases such as Alzheimer's disease (AD),   Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), dementia, stroke, traumatic brain injury (TBI), spinal cord injury, schizophrenia, drug abuse-induced neurotoxicity (i.e. methamphetamine overdoses), and even retinal diseases and glaucoma. This  aims to provide a forum for the dissemination of the latest information on new molecules including both synthetic compounds and natural products as well as novel drug targets associated with neuroprote

20th World Conference on Pharmaceutical Chemistry and Drug Design The principles governing drug targeting in anti-cancer chemotherapy to achieve a tumor-specific targeting are the enzyme responsible for prodrug activation should uniquely be present in the tumor cell. Although there is much evidence of pathways involving enzymes that are aberrantly expressed in tumors, these approaches have found varying success because the differences between healthy and tumor tissues are not normally consistent across different species, individuals, or even tumors. Hypoxia is a common and unique property of cells in solid tumors, and it is therefore a potential mechanism for tumor-specific prodrug activation. The availability of oxygen electrodes has allowed the accurate measurement of oxygen levels in human tumors, which are highly heterogeneous. Polymer-directed enzyme prodrug therapy is a two-step antitumor approach that uses a combination of a polymeric prodrug and a polymer-enzyme conjug

                      In the domain of Pharmaceutical chemistry, biotechnology and medicine, Drug discovery can be defined as an approach to discover new medications or candidate medications. In early days these medications and drugs were identified by discovering the active ingredient with the help of traditional remedies. In history drugs were nothing but the plant extracts, minerals and materials of animal origin. The process of drug discovery involves a melding of many disciplines and interests, transcending the relatively simple process of identifying an active compound in the test tube. The discovery of a novel chemical entity that modulates some aspect of cell or tissue function is but the first step in the drug development process. Once shown to be selective and efficacious, a compound must also be relatively free of toxicity, bioavailable, and marketable before it can be considered as a therapeutic entity. In the last decade, dramatic changes have occurred in th